INDP
Income statement / Annual
Last year (2025), Indaptus Therapeutics Inc's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2025, Indaptus Therapeutics Inc's net income was -$20.85 M.
See Indaptus Therapeutics Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$854.00 K
|
$859.00 K
|
$829.00 K
|
$701.00 K
|
| Gross Profit |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$854.00 K
|
-$859.00 K
|
-$829.00 K
|
-$701.00 K
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$9.34 M
|
$7.25 M
|
$7.62 M
|
$6.32 M
|
$2.52 M
|
$2.66 M
|
$26.66 M
|
$35.40 M
|
$24.30 M
|
$10.07 M
|
| General & Administrative Expenses |
$10.49 M
|
$8.01 M
|
$8.76 M
|
$8.59 M
|
$5.21 M
|
$916.69 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$101.85 K
|
$0.00
|
$0.00
|
$0.00
|
$27.55 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$10.49 M
|
$8.11 M
|
$8.76 M
|
$8.59 M
|
$5.21 M
|
$944.25 K
|
$7.43 M
|
$7.07 M
|
$4.32 M
|
$3.07 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$19.83 M
|
$15.37 M
|
$16.38 M
|
$14.91 M
|
$7.73 M
|
$3.60 M
|
$34.09 M
|
$42.47 M
|
$28.61 M
|
$13.15 M
|
| Cost And Expenses |
$19.83 M
|
$15.37 M
|
$16.38 M
|
$14.91 M
|
$7.73 M
|
$3.60 M
|
$34.95 M
|
$43.33 M
|
$29.44 M
|
$13.85 M
|
| Interest Income |
$0.00
|
$0.00
|
$0.00
|
$588.11 K
|
$17.72 K
|
$0.00
|
$330.00 K
|
$852.00 K
|
$286.00 K
|
$176.00 K
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$15.00 K
|
$23.00 K
|
$17.00 K
|
$16.00 K
|
| Depreciation & Amortization |
$0.00
|
$735.00
|
$1.28 K
|
$1.78 K
|
$1.40 K
|
$852.00
|
$854.00 K
|
$859.00 K
|
$829.00 K
|
$701.00 K
|
| EBITDA |
-$19.83 M |
-$15.37 M |
-$16.38 M |
-$14.91 M |
-$7.73 M |
-$3.60 M |
-$46.09 M |
-$42.56 M |
-$28.61 M |
-$13.15 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
-$1.02 M
|
$343.72 K
|
$955.00 K
|
$588.11 K
|
$17.72 K
|
$15.11 K
|
-$12.02 M
|
-$112.00 K
|
$559.00 K
|
$484.00 K
|
| Income Before Tax |
-$20.85 M
|
-$15.02 M
|
-$15.42 M
|
-$14.32 M
|
-$7.71 M
|
-$3.58 M
|
-$46.96 M
|
-$43.44 M
|
-$28.88 M
|
-$13.36 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$638.00 K
|
$103.00 K
|
$29.00 K
|
$0.00
|
| Net Income |
-$20.85 M
|
-$15.02 M
|
-$15.42 M
|
-$14.32 M
|
-$7.71 M
|
-$3.58 M
|
-$47.60 M
|
-$43.54 M
|
-$28.91 M
|
-$13.36 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-21.58 |
-1.61 |
-1.84 |
-1.73 |
-1.89 |
-0.66 |
-112.74 |
-111.67 |
-130.96 |
-93.38 |
| EPS Diluted |
-21.58 |
-1.61 |
-1.84 |
-1.73 |
-1.89 |
-0.66 |
-112.74 |
-111.67 |
-130.96 |
-93.38 |
| Weighted Average Shares Out |
$966.12 K
|
$9.36 M
|
$8.40 M
|
$8.26 M
|
$4.09 M
|
$5.41 M
|
$422.20 K
|
$389.91 K
|
$220.75 K
|
$143.10 K
|
| Weighted Average Shares Out Diluted |
$966.12 K
|
$9.36 M
|
$8.40 M
|
$8.26 M
|
$4.09 M
|
$5.41 M
|
$422.20 K
|
$389.91 K
|
$220.75 K
|
$143.10 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
